Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Gamma secretase inhibitors

20 evidence topics · 10 sources

DeFi long-term follow-up through December 2024

“Here, long-term nirogacestat efficacy and safety were evaluated in patients randomly assigned to nirogacestat and followed through the final data cutoff date of December 19, 2024.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The median (range) duration of exposure was 33.6 (0.3-61.8) months. Median PFS was not reached. The ORR with up to 4 years of nirogacestat treatment was 45.7% (32 of 70), with three additional partial and three additional complete responses since the primary analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of the 70 patients randomly assigned to nirogacestat in the DB phase, 39 continued in the OLE” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 33 and 15 patients received nirogacestat for at least 3 and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No additional events (progression or death) occurred with additional exposure after year 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The ORR was 34.3%, 41.4%, 44.3%, and 45.7% in patients who received nirogacestat for up to 1, 2, 3, and 4 years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Since the primary analysis, four patients discontinued nirogacestat because of TEAEs between years 2 and 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Optimal duration of treatment and the presence and frequency of additional tumor responses after treatment discontinuation are not well defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Real-world nirogacestat use in the French compassionate use program (DeNi study)